BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
February 19 2021 - 7:00AM
BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a
clinical-stage company developing innovative drug therapies for
liver disease, today announced an interview with Terren Peizer,
Chairman and Chief Executive Officer, will air on The RedChip Money
Report® on Bloomberg TV in the US on Saturday, February 20, at 7
p.m. local time in 73M homes across the United States. The RedChip
Money Report® also airs on Bloomberg International in Europe in
100M homes at 6 pm local time on Sundays.
In the exclusive interview, Peizer discusses the
Company’s development of BIV201, an orphan drug candidate for the
treatment of ascites due to advanced liver cirrhosis. Also
discussed is the global market opportunity and upcoming clinical
trial milestones.
To view the interview segment, please visit:
https://youtu.be/u7G2l36rwn8
“The RedChip Money Report" delivers insightful
commentary on small-cap investing, interviews with Wall Street
analysts, financial book reviews, as well as featured interviews
with executives of public companies.
About BioVie and BIV201BioVie
Inc. is developing BIV201 (continuous infusion terlipressin) an
Orphan Drug candidate for the treatment of ascites due to advanced
liver cirrhosis. First-to-market Orphan therapies typically receive
7 years of market exclusivity in the US for the designated use. The
initial disease target for BIV201 therapy is ascites, which is a
serious complication of advanced liver cirrhosis, and future
development opportunities include hepatorenal syndrome (HRS) and
other life-threatening complications. The Company plans to commence
patient enrollment in its second US Phase 2 clinical trial in the
first quarter of 2021. The trial design is summarized
on www.clinicaltrials.gov, trial identifier NCT04112199. The
FDA has never approved any drug specifically for treating ascites,
and the Company is not aware of any competing drugs in late-stage
development for ascites. The active agent in BIV201, terlipressin,
is approved for use in about 40 countries for the treatment of
related complications of advanced liver cirrhosis but is not
available in the US or Japan.
The Company has invented a patent-pending
prefilled syringe that has been cleared by the FDA for use in our
upcoming Phase 2 trial. This novel BIV201 delivery system is
expected to greatly simplify at-home patient treatment and improve
patient compliance by enabling easy injection of the liquid
concentrate into the IV bag connected to the infusion pump. Room
temperature stability has been achieved for 12 months providing an
important advantage because, to the best of the Company's
knowledge, all other terlipressin products sold globally must be
stored under refrigeration. The novel prefilled syringe format also
avoids the manual mixing of minute (2 – 4 mg) quantities of
terlipressin powder in saline solution, thereby reducing the
possibility of dosing errors during reconstitution and improving
sterility. BioVie has begun applying for global patent protection
for this novel terlipressin delivery system. The Company has also
received Orphan Drug designation for the treatment of hepatorenal
syndrome (HRS) and has FDA Fast Track status. For more information,
visit http://www.biovieinc.com/.
Forward-Looking StatementsThis
press release contains forward-looking statements, which may be
identified by words such as "expect," "look forward to,"
"anticipate" "intend," "plan," "believe," "seek," "estimate,"
"will," "project" or words of similar meaning. Although BioVie Inc.
believes such forward-looking statements are based on reasonable
assumptions, it can give no assurance that its expectations will be
attained. Actual results may vary materially from those expressed
or implied by the statements herein due to the Company's ability to
successfully raise sufficient capital on reasonable terms or at
all, available cash on hand and contractual and statutory
limitations that could impair our ability to pay future dividends,
our ability to complete our clinical trials and to obtain
approval for our product candidates, to successfully defend
potential future litigation, changes in local or national economic
conditions as well as various additional risks, many of which
are now unknown and generally out of the Company's control, and
which are detailed from time to time in reports filed by the
Company with the SEC, including quarterly reports on Form 10-Q,
reports on Form 8-K and annual reports on Form 10-K. BioVie Inc.
does not undertake any duty to update any statements contained
herein (including any forward-looking statements), except as
required by law.
Contact:
INVESTOR RELATIONS:Dave Gentry, CEORedChip
Companies Inc.407-491-4498dave@redchip.com
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioVie (NASDAQ:BIVI)
Historical Stock Chart
From Sep 2023 to Sep 2024